Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases

Keyphrases

• Bone Metastasis 100%
• Zoledronic Acid 100%
• Phase I Trial 100%
• Imatinib Mesylate 100%
• Skeletal-related Events 60%
• Quality of Life 40%
• Bisphosphonates 40%
• Osteolytic Metastasis 40%
• Disease Progression 20%
• Apoptosis 20%
• Platelet-derived Growth factor-BB (PDGF-BB) 20%
• Platelet-derived Growth Factor Receptor (PDGFR) 20%
• Dose-limiting Toxicity 20%
• Phase I Study 20%
• Human Tumors 20%
• Receptor Tyrosine Kinase 20%
• Skeletal Morbidity 20%
• Clinical Efficacy 20%
• Extraskeletal 20%
• Metastatic Cells 20%
• Growth Factor Receptor Tyrosine Kinase 20%
• Microvessel Density 20%

Medicine and Dentistry

• Zoledronic Acid 100%
• Bone Metastasis 100%
• Imatinib 100%
• Phase I Trials 100%
• Quality of Life 28%
• Bisphosphonate 28%
• Neoplasm 14%
• Metastatic Carcinoma 14%
• Cancer Cell 14%
• Kinase Signaling 14%
• Programmed Cell Death 14%
• Protein Tyrosine Kinase 14%
• Disease Exacerbation 14%
• Microvessel 14%
• Platelet Derived Growth Factor 14%
• Platelet Derived Growth Factor Receptor 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Bone Metastasis 100%
• Zoledronic Acid 100%
• Phase I Trials 100%
• Imatinib 100%
• Bisphosphonic Acid Derivative 28%
• Metastasis 14%
• Neoplasm 14%
• Disease Exacerbation 14%
• Protein Tyrosine Kinase 14%
• Platelet Derived Growth Factor Receptor 14%
• Platelet Derived Growth Factor 14%